The trajectory of companies tied to Sildenafil's history presents a challenging investment picture . While the initial surge generated substantial profits , generic alternatives have significantly diminished sales . Investing in connected pharmaceutical companies now requires a discerning assessment of patent safeguards, evolving medical trends , a